InvestorsHub Logo
Followers 58
Posts 10086
Boards Moderated 1
Alias Born 09/21/2016

Re: None

Friday, 10/20/2017 8:49:17 AM

Friday, October 20, 2017 8:49:17 AM

Post# of 459832
This pr was written over a year ago. Is it normal/typical when tests are done to have zero pr follow up? Not suggesting anything just do not know what is usually done, no pass/fail notes? Is it, if silence then...???

Anavex Life Sciences Corp. AVXL, +5.66% shares rose 37.7% in morning trade Wednesday to $4.35 per share after the biotech said it signed an agreement with Biogen Inc. BIIB, -0.63% to test its lead drug candidate. Biogen's testing will examine the remyelination ability of the drug, ANAVEX 2-73, in an effort to treat diseases such as multiple sclerosis. ANAVEX 2-73 is currently in midstage clinical trials for Alzheimer's disease, and has grant funding to be studied for Parkinson's disease, Anavex said. Anavex shares dropped 12.0% over the last three months, compared with a 6.2% rise in the S&P 500 SPX, +0.03%


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News